Table 3.
Classification of patients assessed with a complete pre-transplant study according to whether they were finally transplanted.
| Variable | Total N = 119 |
Trasplanted N = 47 |
Non trasplanted N = 72 |
p |
|---|---|---|---|---|
| Men | 87 (73.1) | 34 (72.3) | 53 (73.6) | 0.88 |
| Age n(SD) | 59.2 (4.6) | 59.1 (4.6) | 59.8 (6.9) | 0.56 |
| BMI | 25 (3.9) | 25.2 (4.2) | 24.9 (4.2) | 0.75 |
| COPD characteristics | ||||
| Moderate exacerbations n(SD) | 0.46 (1.2) | 0.42 (1.3) | 0.49 (1.1) | 0.79 |
| Severe exacerbations n(SD) | 0.85 (1.6) | 0.43 (0.93) | 1.25 (1.9) | 0.015 |
| Total exacerbations n(SD) | 1.33 (2.1) | 0.87 (1.5) | 1.8 (2.5) | 0.035 |
| Dyspnea (mMRC) | 2.95 (0.6) | 3.15 (0.5) | 2.81 (0.6) | 0.0021 |
| FVC (%) | 61.8 (17.1) | 60.96 (17.8) | 62.4 (16.8) | 0.66 |
| FEV1 (%) | 27.5 (10.6) | 25.6 (8.3) | 28.8 (11.8) | 0.11 |
| DLCO (%) | 39.2 (16.5) | 40.3 (16.3) | 38.4 (16.89) | 0.59 |
| 6MWT (m) | 217.8 (138.7) | 192.6 (132.2) | 234.3 (141.4) | 0.126 |
| pO2 (mmHg) | 62.8 (9.8) | 61.9 (9.3) | 63.5 (10.3) | 0.43 |
| pCO2 (mmHg) | 44.8 (7.9) | 44.9 (7.8) | 44.7 (7.8) | 0.89 |
| BODE n(DE) | 6.8 (1.7) | 7.4 (1.4) | 6.4 (1.7) | 0.0026 |
| Sputum determination | 84 (70.6) | 37 (78.7) | 47 (65.3) | 0.116 |
| Positive sputum cultures | 19 (24.7) | 7 (20.6) | 12 (27.9) | 0.459 |
| Basal treatment | ||||
| LABA/ICS | 62 (62.3) | 24 (60) | 38 (64.4) | 0.657 |
| LAMA/LABA | 7 (7) | 0 (0) | 7 (11.9) | 0.024 |
| LAMA/LABA/ICS | 54 (45.4) | 20 (42.5) | 34 (47.3) | 0.61 |
| Roflumilast | 10 (10.1) | 6 (15) | 4 (6.8) | 0.18 |
| Azithromycin | 1 (1) | 0 (0) | 1 (1.7) | 0.4 |
SD: standard deviation; BMI: body mass index; CVF: forced vital capacity; FEV1: forced exhaled volume in the first second; DLCO: carbon monoxide diffusion; 6MWT: six minute walking test; BODE: Body mass index, airflow Obstruction, Dyspnea and Excercise capacity index; LAMA: Long Acting Muscarinic Antagonist; LABA: Long Acting Beta Agonist; ICS: inhaled corticosteroids.